Drugs / Ty21a
Ty21a
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT04543877 | Sep 2022 → Jun 2025 | typhoid fever | USDA, Western Human Nutrition Research Center | Completed | No outcome recorded |
| Phase 0 | NCT04083950 | Dec 2019 → Jan 2022 overdue | typhoid fever | USDA, Western Human Nutrition Research Center | Active not recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT03421236 | Feb 2018 → Dec 2021 | non-invasive bladder urothelial carcinoma | Patrice Jichlinski | Unknown | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT01405521 | Oct 2011 → Dec 2015 | typhoid fever | University of Oxford | Completed | Missed primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT03970304 | Oct 2013 → Aug 2027 expected | typhoid fever | University of Maryland, Baltimore | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-05-20 | Emergent BioSolutions | Regulatory Emergent BioSolutions Announces Granting of Marketing Authorization in Five EU Countries for Its Oral Typhoid Vaccine; Expands Availability Across Europe emergentbiosolutions.com ↗
The harmonized SmPC aligned the age indication and expanded the revaccination interval from one to three years following the most recent vaccination. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-06-29 | Scandinavian Biopharma AB | Scandinavian Biopharma announces marketing and distribution agreement with Emergent to relaunch the oral typhoid vaccine (Ty21a) in Germany scandinavianbiopharma.se ↗ |
| 2019-05-20 | Emergent BioSolutions | Emergent BioSolutions Announces Granting of Marketing Authorization in Five EU Countries for Its Oral Typhoid Vaccine; Expands Availability Across Europe emergentbiosolutions.com ↗ |
| 2019-03-19 | Daewoong Pharmaceutical Co. LTD. | Daewoong Pharmaceutical acquires the sales rights for Vivotif, an orally injected typhoid fever vaccine. daewoong.co.kr ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ty21a | “The licensed Ty21a vaccine strain of S. enterica Typhi is routinely used by travelers to countries where typhoid is common.” NCT04083950 ↗4“Oral typhoid vaccine Ty21a confers a moderate level of long-lived protection (5-7 years) in the field.” PMID 32098623 ↗ Feb 2020 |
| Known as | Ty21a Typhoid Oral Vaccine | “Ty21a Typhoid Oral Vaccine” NCT03970304 ↗1“Ty21a Typhoid Oral Vaccine” NCT04083950 ↗ |
| Known as | Vivotif | “intravesical instillation of Ty21a/Vivotif, the oral vaccine against typhoid fever” PMID 36212980 ↗ Oct 2022 |
| Modality | Vaccine | “Ty21a vaccine recipients” PMID 27533046 ↗ Aug 2016 |
| Route | Oral | “3 oral doses” NCT01405521 ↗ |